Viking Therapeutics Q1 net loss $19.5M; VK2735 shows up to 7.8% weight loss

Viking Therapeutics, Inc.

2023-Q1 EPS reported -$0.25

Net loss $19.5M ($0.25/sh) vs $16.1M ($0.21/sh) in Q1 2022; R&D $11.0M, G&A $9.5M.
Cash and investments $135.7M at March 31; pro forma with $287.5M offering totals ~$406M.
VK2735 Phase 1: up to 7.8% mean weight loss from baseline (6% placebo-adjusted); half-life 170-250h; no discontinuations for GI AEs.
Phase 2b VOYAGE study of VK2809 for NASH fully enrolled; primary endpoint data expected in Q2 2023.
Phase 1 oral formulation of VK2735 initiated; data expected 2H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Viking Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

announced its financial results for the first quarter ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

Viking Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-014788

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.